# Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT02057770** · PHASE1 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 25 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** busulfan
- **DRUG:** fludarabine phosphate
- **RADIATION:** total-body irradiation (TBI)
- **PROCEDURE:** Stem cell transplant
- **DRUG:** cyclophosphamide
- **DRUG:** tocilizumab

## Key facts

- **NCT ID:** NCT02057770
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02-28
- **Primary completion:** 2018-01-12
- **Final completion:** 2018-03-23
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Low accrual rate
- **Last updated:** 2018-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02057770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02057770, "Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02057770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*